🇺🇸 FDA
Pipeline program

Nabiximols

GWSP19066

Phase 3 small_molecule completed

Quick answer

Nabiximols for Spasticity in Participants With Multiple Sclerosis is a Phase 3 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Jazz Pharmaceuticals plc
Indication
Spasticity in Participants With Multiple Sclerosis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials